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Summary
Background As the COVID-19 pandemic continues, national-level surveillance platforms with real-time individual 
person-level data are required to monitor and predict the epidemiological and clinical profile of COVID-19 and inform 
public health policy. We aimed to create a national dataset of patient-level data in Scotland to identify temporal trends 
and COVID-19 risk factors, and to develop a novel statistical prediction model to forecast COVID-19-related deaths 
and hospitalisations during the second wave.
Methods We established a surveillance platform to monitor COVID-19 temporal trends using person-level primary 
care data (including age, sex, socioeconomic status, urban or rural residence, care home residence, and clinical risk 
factors) linked to data on SARS-CoV-2 RT-PCR tests, hospitalisations, and deaths for all individuals resident in 
Scotland who were registered with a general practice on Feb 23, 2020. A Cox proportional hazards model was used to 
estimate the association between clinical risk groups and time to hospitalisation and death. A survival prediction 
model derived from data from March 1 to June 23, 2020, was created to forecast hospital admissions and deaths from 
October to December, 2020. We fitted a generalised additive spline model to daily SARS-CoV-2 cases over the previous 
10 weeks and used this to create a 28-day forecast of the number of daily cases. The age and risk group pattern of cases 
in the previous 3 weeks was then used to select a stratified sample of individuals from our cohort who had not 
previously tested positive, with future cases in each group sampled from a multinomial distribution. We then used 
their patient characteristics (including age, sex, comorbidities, and socioeconomic status) to predict their probability 
of hospitalisation or death.
Findings Our cohort included 5 384 819 people, representing 98·6% of the entire estimated population residing in 
Scotland during 2020. Hospitalisation and death among those testing positive for SARS-CoV-2 between March 1 and 
June 23, 2020, were associated with several patient characteristics, including male sex (hospitalisation hazard ratio 
[HR] 1·47, 95% CI 1·38–1·57; death HR 1·62, 1·49–1·76) and various comorbidities, with the highest hospitalisation 
HR found for transplantation (4·53, 1·87–10·98) and the highest death HR for myoneural disease (2·33, 1·46–3·71). 
For those testing positive, there were decreasing temporal trends in hospitalisation and death rates. The proportion of 
positive tests among older age groups (>40 years) and those with at-risk comorbidities increased during October, 2020. 
On Nov 10, 2020, the projected number of hospitalisations for Dec 8, 2020 (28 days later) was 90 per day (95% prediction 
interval 55–125) and the projected number of deaths was 21 per day (12–29).
Interpretation The estimated incidence of SARS-CoV-2 infection based on positive tests recorded in this unique 
data resource has provided forecasts of hospitalisation and death rates for the whole of Scotland. These findings 
were used by the Scottish Government to inform their response to reduce COVID-19-related morbidity and 
mortality.
Funding Medical Research Council, National Institute for Health Research Health Technology Assessment 
Programme, UK Research and Innovation Industrial Strategy Challenge Fund, Health Data Research UK, Scottish 
Government Director General Health and Social Care.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Following its emergence in Wuhan, China, in 
December, 2019, SARS-CoV-2 has spread throughout the 
world.1 In a subset of individuals, SARS-CoV-2 causes a 
severe form of disease, leading to hospitalisation, 
admission to intensive care units (ICUs), or death. 
COVID-19 was declared a pandemic by WHO on 
March 11, 2020.
A key aspect of the epidemiological response to 
COVID-19 has been the use of individual patient 
health-care data—eg, data for those with a positive 
RT-PCR test for SARS-CoV-2 who have been hospitalised 
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or died.2 As the COVID-19 pandemic continues, rich, 
real-time individual person-level data are needed to better 
understand the natural population-based dynamics of 
the disease.3 Three different model types—susceptible-
exposed-infectious-recovered or susceptible-infectious-
recovered models, agent-based models, and curve-fitting 
models—have been used to project possible numbers 
of confirmed (new) cases, hospitalisations, and deaths 
under different scenarios.4,5 National-level surveillance 
platforms can also help to monitor and predict the 
epidemiological and clinical profile of COVID-19, thus 
informing public health policy. These platforms have 
the advantage of including a complete unselected 
population, in which disease introductions are common 
and community transmission widespread.6 However, 
most available individual-level data come from specific 
institutions, highly selected populations, or limited 
country-wide coverage (eg, limited to one city3 or patients 
with more severe disease2). 
We aimed to develop a national dataset of individual 
patient-level primary and secondary care, mortality, and 
virological and serological testing data in Scotland to 
assess the temporal progression of the COVID-19 
pandemic, risk factors for COVID-19-related hospitalisa-
tion and death, and temporal trends in hospitalisations 
and deaths by age and risk factor groups. We also aimed 
to develop a novel statistical prediction model to forecast 
COVID-19-related deaths and hospitalisations in the 
second COVID-19 wave in Scotland.
Methods 
Study design 
We linked anonymised individual patient-level primary 
care, secondary care, mortality, and virological and 
serological testing data in Scotland and used this national 
dataset to investigate the temporal progression of 
COVID-19 in residents of Scotland who had not previously 
tested positive for SARS-CoV-2. Based on these data, we 
identified risk factors for COVID-19-related hospitalisation 
and death and temporal trends in the proportion of 
hospitalisations and deaths by age and risk factor groups 
among those with a positive RT-PCR test for SARS-CoV-2. 
Additionally, we developed a novel 28-day statistical 
prediction model to forecast COVID-19-related hos pitalisa-
tions and deaths after a positive test during the second 
COVID-19 wave in Scotland (ie, from June 28, 2020).
Ethical approval for this study was granted from 
South East Scotland Research Ethics Committee 02 
(12/SS/0201). The Public Benefit and Privacy Panel 
Committee of Public Health Scotland approved the 
Research in context
Evidence before this study
As the COVID-19 pandemic continues, rich, real-time individual 
person-level data are required to better understand the natural 
population-based dynamics of the disease. National-level 
surveillance platforms can help to monitor and predict the 
epidemiological and clinical profile of the COVID-19 pandemic 
and thus inform public health policy. These platforms have the 
advantage of including a complete unselected population, 
with disease introductions and community transmission. 
We searched Google Scholar on Sept 10, 2020, for English-
language articles relating to national-level surveillance 
platforms for COVID-19, using the terms “SARS-CoV-2,” 
“COVID-19,” “surveillance platforms,” “unselected population,” 
and “individual-level data”. However, in the six studies 
identified, we found that most available individual-level data 
could only identify patients from specific institutions, highly 
selected populations, or with limited country-wide coverage 
(eg, limited to patients with severe disease or to only one city).
Added value of this study
To our knowledge, we have created the first individual patient-
level dataset from all primary care, secondary care, mortality, 
and virological testing data on almost an entire national 
population. We used this national dataset to investigate the 
temporal progression of COVID-19 cases, morbidity, and 
mortality in individuals initially free of the disease across 
Scotland. Based on these data, we created a novel statistical 
prediction model for COVID-19 deaths and hospitalisations 
and used it to accurately forecast the expected impact of the 
second wave (beginning June 28, 2020) on the Scottish health-
care system. COVID-19-related hospitalisations among people 
testing positive for SARS-CoV-2 within 14 days were 
associated with being male, and having chronic heart, kidney, 
or respiratory disease; depression; diabetes; haematological 
malignancy; hypertension; immunosuppression; pregnancy; 
splenectomy and anaemia; or transplantation. COVID-19 
deaths within 28 days after a positive test were associated with 
being male or a care home resident, having chronic heart or 
kidney disease, dementia, haematological malignancy, 
splenectomy and anaemia, myoneural disease, or having home 
oxygen. We found decreasing temporal trends in 
hospitalisation and death rates for those testing positive for 
SARS-CoV-2 during the second wave. However, we identified 
an emerging pattern in the second wave of an increasing 
incidence and proportion of positive SARS-CoV-2 tests in older 
age groups with multimorbidity.
Implications of all the available evidence
These results signalled the need to consider public health 
interventions to reduce the numbers of hospitalisations and 
deaths that would otherwise follow. The estimated incidence of 
infection based on positive tests recorded in this unique data 
resource yielded accurate forecasts of hospitalisation and death 
rates for the whole of Scotland. These findings were used by the 
Scottish Government to inform their response to COVID-19.
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linkage and analysis of the de-identified datasets for this 
project (1920-0279).
Data sources 
Almost all residents of Scotland (including children) are 
registered with primary care, which provides a com-
prehensive array of health-care services that are free at the 
point of care, including the issuing of prescriptions for 
medications. Access to secondary care is typically through 
a general practitioner (GP) based within a primary care 
practice or via the emergency department or out-of-hours 
primary care services. Additionally, during the acute 
phase of the pandemic (ie, from March 23, 2020), 
community-based COVID-19 hubs (GP-led services 
designed to separate patients with COVID-19 and reduce 
the risk of nosocomial infections) were established.
We used data from all 940 Scottish primary care 
practices.7 Clinical data collected by primary care in 
Scotland have consistently been shown to be of high 
quality (90% completeness and accuracy8) and their 
value for epidemiological research has been repeatedly 
demonstrated.9–12 These data were linked to three other 
national datasets: the Electronic Communication of 
Surveillance in Scotland (national database for all 
virology testing), the Scottish Morbidity Record (which 
records hospitalisations, including ICU stay), and National 
Records Scotland (for death certification; appendix p 1).13
Our cohort included all patients of any age registered 
with any primary care practice in Scotland on Feb 23, 2020, 
who were followed up from March 1, 2020, to Nov 8, 2020. 
Risk factors and outcomes 
We assessed several factors potentially associated with 
COVID-19 morbidity and mortality and included them in 
our prediction model: sex, age, socioeconomic status, 
urban or rural residence, and risk groups based on 
clinical characteristics, all of which were identified from 
primary care records. All participants were included, 
regardless of data availability; participants with missing 
socioeconomic status were included as a separate 
category. Socioeconomic status was determined on 
the basis of the Scottish Index of Multiple Deprivation 
(SIMD). The SIMD classification is based on deprivation 
quintiles: quintile 1 refers to the most deprived and 
quintile 5 refers to the most affluent. SIMD was assigned 
according to residential postcode. Urban or rural 
residence was classified using the urban rural six-fold 
classification (UR6), which is the definition used to 
determine rurality in Scotland: 1 is assigned to large 
urban areas (ie, ≥125 000 residents) and 6 is assigned to 
remote rural areas (ie, <3000 residents and >30 min drive 
to urban areas).14 Clinical risk groups were defined using 
the primary care clinical Read coding system, with codes 
grouped into 17 categories: care home residence, chronic 
heart disease, chronic kidney disease, chronic liver 
disease, chronic respiratory disease, dementia, depres-
sion, diabetes, haematological malig nancy, home oxygen, 
hypertension, immunosuppression, multiple sclerosis 
and degerenative disease, myoneural disease, splenec-
tomy and anaemia, trans plantation, and pregnancy 
(appendix pp 2–3). The included conditions were 
considered to be potential COVID-19 risk factors based 
on previous studies focusing on severe disease from 
influenza virus and from early epidemiological data.15,16 
Patients were classified as members of a clinical risk 
group if there was a record of a Read code associated with 
the relevant diagnosis in the patient’s primary care 
record before Feb 23, 2020.
For COVID-19-related hospitalisations, we included 
individuals who were hospitalised within 14 days 
following a positive RT-PCR test for SARS-CoV-2, 
including those who tested positive while hospitalised, or 
those who were hospitalised with an admission diagnosis 
of COVID-19. COVID-19-related deaths were all-cause 
deaths occurring within 28 days after a positive test for 
SARS-CoV-2 that were registered with National Records 
Scotland and included death certification, or deaths with 
COVID-19 on the death certificate as the cause of death.
Forecasting model and statistical analysis 
Our novel survival prediction model is based on clinical 
and demographic characteristics of individuals with a 
positive RT-PCR test for SARS-CoV-2, in addition to age; 
sex; UR6; number of comorbidities (ie, risk groups), 
including care home residency; and socioeconomic status. 
The predic tion model is derived from data from March 1 
to June 23, 2020 (the first wave of the COVID-19 pandemic 
in Scotland). Clinical risk group information is based on 
the clinical characteristics of the cohort on March 1, 2020, 
and used to calculate the number of comorbidities each 
individual had.
For those who tested positive for SARS-CoV-2 in 
Scotland during the first wave, a Cox proportional 
hazards model was used to estimate the association 
between each of the clinical risk groups and time to 
hospitalisation or death from the date the person had a 
positive test result. Risk factors informative to the model 
were used; these factors were then used to calculate the 
count of comorbidities that was included in the prediction 
model. Demographic data (age, sex, socioeconomic 
status, and UR6) were also included in the prediction 
model. Age (in years) and time (measured in days from 
March 1, 2020) were included in the model as penalised 
splines. Backwards selection of the risk group variables 
was used to obtain a parsimonious model and five-fold 
cross-validation to estimate concordance.
Forecasts from June 24 to Nov 8, 2020, were produced 
each week based upon those testing positive in this 
period. For each positive case, using their risk profile 
(eg, age, sex, and number of comorbidities), we calculated 
individual risk of becoming hospitalised (within 14 days 
after a positive test) or death (within 28 days after a 
positive test), on the basis of the identical characteristics 
of patients who previously tested positive for SARS-CoV-2 
See Online for appendix
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and their outcomes. The last forecast we present is for 
28 days after Nov 10, 2020.
We did not forecast the temporal effect (time to 
hospitalisation or death following a positive test) using 
the spline term, but instead used the latest values of the 
temporal effect from the observed period (ie, June, 2020). 
Each week, we fitted a generalised additive spline model 
to the daily SARS-CoV-2-positive cases over the previous 
10 weeks and used this to forecast the total number of 
cases per day over the following 4 weeks.17 The age and 
risk group pattern of cases in the previous three weeks 
was then used to select a stratified sample of individuals 
from our cohort who had not previously tested positive 
(eg, data from Oct 19 to Nov 8, 2020, were used for 28-day 
predictions starting from Nov 10). Future cases in each 
group were then sampled from a multinomial 
distribution, with the total cases coming from the spline 
growth model. For example, if we forecasted 1000 cases 
the next day and 5% of cases in the previous week were 
aged 65 years or older and had two comorbid conditions, 
we then sampled 50 people who had these characteristics 
out of the total previously uninfected population and 
used their patient characteristics (including age, sex, 
comorbidities, socioeconomic status, and UR6) values to 
predict their probability of being hospitalised or dying. In 
this way, the clinical char acteristics of future cases were 
used to forecast hospital admissions and deaths.
Forecasts are based on extrapolation of the cases 
testing positive and scenarios (eg, non-pharmacological 
public health interventions to suppress transmission) 
that assume a halving in the growth of positive cases and 
a reduction to a growth rate of zero. We also produced a 
set of concordance values for the model (with values 
>0·80 indicating very good concordance), fitting a period 
up to June 23, 2020, and then for two test periods 
representing different stages of the second wave. During 
the first test period (June 24 to Sept 30, 2020), there were 
low numbers of COVID-19 hospitalisations and deaths. 
The second period (Oct 1 to Nov 8, 2020) represents a 
time when hospitalisations and deaths were much 
higher.
Predictions were sampled from a probability distribu-
tion, with predictions run 20 times to allow calculation of 
95% prediction intervals (PIs).
Analyses were done in R (version 3.6.1). All code 
developed for this forecasting method has been included 
in our GitHub area.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
Our cohort included 5 384 819 people registered with a 
GP on Feb 23, 2020, representing 98·6% of the entire 
estimated population residing in Scotland during 2020 
(estimated at 5 463 300 from the 2018 census).
Based on data from March 1 to June 23, 2020, 
COVID-19-related hospitalisations and deaths were 
associated with several patient characteristics including 
male sex (hazard ratio [HR] for hospitalisation 1·47, 
95% CI 1·38–1·57; HR for death 1·16, 1·49–1·76). Among 
comorbidities, the highest HR for hospitalisation was 
found for transplantation (4·53, 1·87–10·98) and the 
highest HR for death was found for myoneural disease 
(2·33, 1·46–3·71; appendix pp 4–5). COVID-19-related 
hospitalisations were also associated with having chronic 
heart, kidney, or respiratory disease; depression; diabetes; 
haematological malignancy; hypertension; immuno-
suppression; pregnancy; and splenectomy or anaemia 
(appendix p 4). COVID-19 death was also associated with 
being a care home resident, having chronic heart or 
kidney disease, dementia, having a haematological 
malignancy, splenectomy or anaemia, or having home 
oxygen (appendix p 5). Decreased risk of COVID-19-
related hos pitalisation and mortality was associated with 
affluent socioeconomic status (SIMD quintile 5; appendix 
pp 4–5).
774 491 people who were tested for SARS-CoV-2 using 
RT-PCR over the study period were linked into the study 
population, representing 14·4% of the cohort (appendix 
p 7). 223 866 people were tested in the period up to 
June 23, 2020, with a further 526 591 newly tested 
between June 24 and Nov 8, 2020. The number of tests 
per week increased during the study period (appendix p 8).
Figure 1: Extrapolation of cases testing positive for SARS-CoV-2



















For the code see https://github.
com/EAVE-II
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SARS-CoV-2 was confirmed in 75 173 (9·7%) of the 
774 491 Scottish residents tested using RT-PCR up to 
Nov 8, 2020, with extrapolation of positive cases up to 
December shown in figure 1. There is evidence of a 
slowing down or turning point in the daily number of 
SARS-CoV-2 cases around Oct 17, 2020, probably due to 
restrictions imposed on household visits and hospitality 
on Sept 23, followed by further restrictions on hospitality 
on Oct 9. Dynamics in test positivity varied over time by 
sex, age, risk group, and socioeconomic status. During 
the initial phase of the pandemic, the proportion of 
positive tests among female individuals was around 25% 
(vs 75% among male individuals); this percentage 
increased substantially to more than 65% by June, 2020, 
dropped during July and August to less than 50%, and 
finally increased to 55% by October, 2020 (appendix p 9). 
Up to June 23, 2020, 25% of those testing positive were 
aged 80 years or older. The percentage of young adults 
(aged 18–39 years) testing positive rose from 25% in 
April to 50% in August, 2020; this percentage declined 
from September, 2020, onwards, with concomitant 
increases among those older than 40 years of age 
(appendix p 10). During the first wave, 10% of those 
testing positive had five or more clinical conditions 
deemed to be COVID-19 risk factors; this percentage 
dropped to around 2% by August, 2020, followed by an 
increase to 15% by October. There was a steady rise in the 
percentage of those testing positive who did not have 
Figure 2: COVID-19-related hospitalisations and deaths by age and time trends
(A) Hospitalisation rate by age during the first wave (March 1 to June 23, 2020), relative to 30 years of age. (B) Hospitalisation rate over time during the first wave, relative 
to day 31 (April 1, 2020). (C) Death rate by age during the first wave, relative to 30 years of age. (D) Death rate over time during the first wave, relative to day 31 








































20 40 60 80 100





























Number of risk groups All risk groups
0 1 2 3–4 ≥5
0–11 years 0·0315 0·000852 0·00426 0 0 0·0366
12–17 years 0·0456 0·00213 0·00596 0 0 0·0537
18–29 years 0·304 0·0266 0·0614 0·00565 0·000807 0·398
30–39 years 0·0842 0·0168 0·0158 0·00368 0 0·120
40–64 years 0·144 0·0729 0·0493 0·0351 0·00420 0·306
≥65 years 0·0119 0·0212 0·0195 0·0239 0·00885 0·0854
All ages 0·621 0·140 0·156 0·0683 0·0139 1·00
This age and risk group pattern was used to select a stratified sample of individuals who had not previously tested 
positive from the cohort. Cases were sampled from a multinomial distribution and total cases came from the spline 
growth forecasting model. 
Table: Proportion of cases by age and risk factors in the last 3 weeks of the study (Oct 19 to Nov 8, 2020) 
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any relevant clinical conditions to a peak of more than 
70% of cases in August, followed by a decline to 50% in 
October, 2020 (appendix p 11). 30% of people testing 
positive at the beginning of the pandemic were among 
the most affluent (SIMD quintile 5); this propor tion 
declined to 10% by July, 2020, and then increased slightly 
to 18% by October, 2020. Overall, a higher proportion in 
large and other urban areas tested positive during 2020 
than in remote small towns and remote rural areas 
(appendix p 11). No discernible changing temporal 
patterns were identified for urban versus rural areas.
5104 (6·8%) of 75 173 people who tested positive for 
SARS-CoV-2 were hospitalised for COVID-19 up to 
Nov 8, 2020. Of the 5 384 819 people in the cohort, 
3796 died of COVID-19. The COVID-19 death rate in 
Scotland during the studied period was 703 deaths per 
1 million population.
During the first wave (up to June 23, 2020), relative 
hospitalisation and death rates among individuals testing 
positive for SARS-CoV-2 using RT-PCR decreased over 
time (figure 2B, D). Hospitalisation rates increased with 
age, peaking at around 75 years of age with a decline 
thereafter (figure 2A). Deaths also increased with age, 
plateauing at around 80 years of age (figure 2C).
The age and risk pattern of the 25 827 RT-PCR-positive 
cases in the last 3 weeks of the study is shown in the table, 
presented as breakdown of proportions by age and 
number of risk groups; the age and risk pattern for all 
tests in the previous 3 weeks can be found in the 
appendix (p 6). The proportion of older people and people 
with comorbidities testing positive for SARS-CoV-2 
increased from the end of the first test period (Aug 29) to 
Oct 24, 2020 (figure 3; appendix pp 10–11).
The concordance value for hospitalisations over the 
period March 1 to June 23, 2020, was 0·84. For the two 
test periods (June 24 to Sept 30, 2020, and Oct 1 to 
Nov 8, 2020), the concordance for hospitalisations 
was 0·80 for each period. The concordance value for 
deaths was 0·84 in the period from March 1 to June 23, 
0·93 for the first test period (June 24 to Sept 30), 
and 0·92 for the second test period (Oct 1 to Nov 8).
By Oct 15, 2020, there were about 70 hospitalisations 
for COVID-19 and ten COVID-19-related deaths per day 
in Scotland. On Nov 10 (28 days later) hospitalisations on 
Dec 8, 2020, were forecast to increase to 90 per day 
(95% PI 55–125) and deaths to 21 per day (12–29; figure 4). 
These forecasts assumed no changes in the growth 
of the epidemic or in the demographic and clinical 
characteristics of patients testing positive after Nov 10.
As an illustration of the changing dynamics, forecasts 
made on Oct 24 for hospitalisations and deaths up to 
Nov 21, 2020, are presented for different SARS-CoV-2 
growth rates (appendix pp 13–15). The original forecasts 
showed increasing hospitalisations and deaths, reaching 
290 hospitalisations (95% PI 260–320) and 30 deaths 
(20–55) per day by mid-November (appendix p 13). If the 
growth rate of SARS-CoV-2 was halved, the forecast at the 
Figure 3: Distribution of 
RT-PCR-confirmed 
SARS-CoV-2 cases by age and 
risk groups in August, 
October, and November, 2020
Data shown in panels C and D 
were used in the forecast, with 
panels Aand B illustrating the 
distribution at earlier 
timepoints. (A) About 
150 positive cases per day 
were recorded in the week 
beginning Aug 29, 2020 
(131 202 total tests). (B) About 
1000 positive cases per day 
were recorded in the week 
beginning Oct 10, 2020 
(117 920 total tests). 
(C) About 1400 positive cases 
per day were recorded in the 
week beginning Oct 17, 2020 
(126 972 total tests). 
(D) About 1000 positive cases 
per day were recorded in the 
week beginning Nov 1, 2020 
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same timepoint became 220 hospitalisations per day 
(190–250) and 25 deaths per day (16–34; appendix p 14). If 
the growth rate of SARS-CoV-2 was reduced to zero, the 
forecast at the same timepoint showed hospitalisations 
levelling off at 155 per day (130–175) and deaths at 
18 per day (10–27; appendix p 15). Zero growth reflects 
the situation on Nov 11, 2020, following the introduction 
of movement restrictions in Scotland during the 
mid-October school break and continued restrictions for 
most of central Scotland.
Discussion 
In this study, a whole-population dataset with individual 
patient-level data was created and used to analyse the 
temporal patterns of the COVID-19 pandemic in Scotland 
in 2020. We found that morbidity and mortality occurred 
disproportionately in the most socioeconomically deprived 
and in those with the most clinical risk factors. Numbers 
of positive RT-PCR tests increased rapidly and peaked 
among women and in the oldest age groups both before 
and immediately after the first national lockdown 
(March 23 to May 29, 2020). During the initial wave, up to 
June, 2020, COVID-19 hospitalisation and mortality rates 
decreased for those testing positive, with mortality being 
particularly high for the oldest (≥80 years) residents of 
Scotland. In the second wave, groups with lower levels of 
SARS-CoV-2 infection during the first wave (younger, 
male, and affluent groups) saw increases in infection rates
The observed number of COVID-19-related hospitalisa-
tions on Dec 8, 2020 (n=104), was 14 higher than our 
forecasted prediction of 90, and was within our 95% PI 
(55–125).18 The observed number of deaths on the same 
day (n=27) was six deaths higher than our forecast, and 
was also within our 95% PI (12–29).
A substantial strength of this study was our ability to 
describe whole-population data, which contrasts with 
previous studies that have, at best, been able to study only 
subsamples of the national population.19,20 Our whole-
population dataset includes patients registered with all 
general practices in Scotland.13 Almost all health care in 
Scotland is provided via the National Health Service 
(NHS), with almost all people resident in Scotland 
registered with a GP. Each person in Scotland has a unique 
identifier that is used in every health contact with the 
NHS. This Community Health Index21 number allows for 
highly accurate data linkage at an individual patient level to 
national, routinely collected data sources. These results are 
likely to have excellent generalisability across the UK and 
reasonable generalisability to countries with similar health 
systems, population structures (predominant ethnicity 
90% White, with a population density of 67·2 people 
per km²), and experiences with the pandemic. Our rapid 
access to this data source through the NHS National 
Institute for Health Research Pandemic Preparedness 
Portfolio enabled us to quickly enhance a pandemic 
influenza platform (EAVE I) to provide granular real-time 
data on the COVID-19 pandemic.22,23
This dataset has the advantage of being populated 
entirely by routinely collected data, and consequently can 
be used for clinical practice. However, given the 
observational nature of the study, there is potential for 
confounding, due to insufficiently granular, or a lack of, 
measurement of variables. A small proportion of people 
Figure 4: Forecasted hospitalisations and deaths (from Nov 10, 2020) among those who tested positive for 
SARS-CoV-2
Hospital admissions (A) and deaths (B) among people who tested positive for SARS-CoV-2 per day. The red line 
shows mean predictions, with 95% prediction intervals. The model is fitted to data up to June 23, 2020, and the 
predictions from July 1, 2020, to Nov 8 are based on the clinical characteristics of the tested positive cases. 
The predictions from Nov 10 (the dotted line) onwards are based on forecasted cases. The saw-tooth pattern in 
the hospitalisation predictions in September and October is due to the weekend pattern of testing, which led to a 
relatively short time between patients testing positive and being hospitalised. This is averaged out in the 
projections into the future.
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resident in Scotland might not be registered in primary 
care, including the homeless (those without permanent 
abode) and travelling people. Although the prediction 
models use up-to-date data, they are still sensitive to the 
fitted temporal trend. This temporal trend was most 
imprecise at the end of the observed data series 
(June 23, 2020), and these values were used in the 
prediction. The forecasts assume that recent trends will 
persist and that no further local restrictions are 
implemented (eg, in response to a more susceptible case 
mix of people being infected). The predictions also 
assumed no change in the relationship between clinical 
and demographic characteristics and outcomes. Further-
more, change in accessibility of testing over time could 
result in differential misclassification, altering the case 
mix of those being tested. During the second wave, there 
was a move towards proactive case finding, early warning 
in key sectors including schools, and increased testing, 
leading to identification of more asymptomatic patients.24 
In particular, the changing test access criteria make it 
difficult to interpret differences in time from positive test 
to hospitalisation and death during the first and second 
waves. Prolongation of the interval between detection of 
infection and death (an estimated 17·8 days between 
onset and death17) might have resulted in underestimation 
of deaths forecast in the short term (eg, 0–20 days). Bias 
might have also occurred due to differences in health-
care-seeking behaviours between patients; in particular, 
health-care workers might have been less likely to seek 
formal medical advice or assessment, which might have 
decreased the effect size among this group.25 Unmeasured 
confounders might also have influenced our estimates. 
The statistical model approach adopted in our analysis 
has advantages and disadvantages compared with a 
dynamic transmission model. The advantage of our 
statistical model approach is that it is likely to be more 
parsimonious and it is not necessary to understand 
why the interventions worked to fit our models. A 
disadvantage is that further refinements will be needed to 
improve the model as more data become available—eg, 
transmission modelling and who-acquires-infection-
from-whom matrices.26
Given the early and wide-ranging lockdown measures 
imposed on all people resident in Scotland from 
early 2020, the initial impact of COVID-19 on the Scottish 
population was substantial. Despite high adherence to 
lockdown measures,27 multiple introductions of infec-
tion, particularly from Europe, caused an accelerated 
outbreak.6 Increasing proportions of at-risk people (those 
with older age and more at-risk comorbidities) testing 
positive for SARS-CoV-2 resulted in substantial morbidity 
and mortality among these groups. Various measures, 
such as test, trace, and isolate; shielding;28 continually 
updated evidence-based guidance for care homes; and 
prioritised personal protective equipment, have none-
theless resulted in these groups being better protected in 
subsequent pandemic waves. Emerging patterns in the 
second wave included an increasing number of test-
positive cases in late August for all age groups younger 
than 40 years. This is likely to have been due to the 
opening of schools on Aug 11, 2020, resulting in increased 
household transmission in Scotland. A pattern of 
increasing incidence and proportion of positive tests in 
older age groups with multimorbidity was also of 
concern, signalling the need to consider public health 
interventions to reduce the number of hospitalisations 
and deaths that might have otherwise followed. Together 
with other public health surveillance data, policy makers 
were able to use these data to inform decisions on when 
physical distancing measures should be introduced.29 
This novel forecasting method is also providing an 
indication of the relative success (or otherwise) of public 
health measures at a population level.
To our knowledge, this is the first national dataset to 
contain near real-time patient-level data for the whole 
population. The linkage of multiple data sources, 
including the rich data available from primary care and 
all SARS-CoV-2 laboratory testing, hospitalisations, 
and deaths, means that accurate and timely forecasting 
can be carried out and used to inform government 
policy.
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